دورية أكاديمية
Endothelin-1 indicates unfavorable prognosis in primary high-grade non-muscle-invasive urothelial bladder cancer
| العنوان: | Endothelin-1 indicates unfavorable prognosis in primary high-grade non-muscle-invasive urothelial bladder cancer |
|---|---|
| المؤلفون: | Mitrakas L., Gravas S., Karasavvidou F., Zachos I., Karatzas A., Oeconomou A., Koukoulis G., Tzortzis V., Papandreou C. |
| المصدر: | Archivio Italiano di Urologia e Andrologia ; https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111953268&doi=10.4081%2faiua.2021.2.143&partnerID=40&md5=495ab176855d417154841432a796d85bTest |
| سنة النشر: | 2021 |
| المجموعة: | University of Thessaly Institutional Repository / Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας |
| مصطلحات موضوعية: | BCG vaccine, endothelin 1, immunological adjuvant, adult, age, aged, Article, bladder cancer, cancer grading, cancer growth, cancer prevention, cancer prognosis, cancer recurrence, cancer survival, cohort analysis, deterioration, female, follow up, histopathology, human, immunohistochemistry, major clinical study, male, non muscle invasive urothelial bladder cancer, outcome assessment, primary tumor, progression free survival, prospective study, protein expression, recurrence free survival |
| الوصف: | Objective: To conduct a prospective study of the potential prognostic role of endothelin-1 (ET-1) in a cohort of primary high-grade non-muscle-invasive urothelial bladder cancer patients, who were treated with adjuvant intravesical Bacillus Calmette-Guérin (BCG). Material and methods: Patients with primary high-grade nonmuscle- invasive urothelial bladder cancer, who received postoperatively induction and maintenance BCG therapy, were prospectively included. Recurrence and progression were histologically proven. Immunohistochemical staining for ET-1 was assessed. Epidemiological, pathological and clinical parameters as well as the expression of ET-1 in tumor specimens were statistically analyzed for recurrence, progression, recurrence-free survival (RFS) and progression-free survival (PFS). Results: ET-1 associates significantly with recurrence (p = 0.000), progression (p = 0.000), RFS (p = 0.000) and PFS (p = 0.000). The patient's age is also significant for recurrence (p = 0.003, OR = 1.273 95% CI: 1.086-1.492) and RFS (p = 0.013). Conclusions: ET-1 seems to deteriorate prognosis in patients suffering from primary high-grade non-muscle-invasive urothelial bladder cancer, who are treated with adjuvant BCG instillations. Furthermore, the patient's age associates with an increased likelihood for recurrence. © 2021 Edizioni Scripta Manent s.n.c. All rights reserved. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 11243562 |
| العلاقة: | http://hdl.handle.net/11615/76668Test |
| DOI: | 10.4081/aiua.2021.2.143 |
| الإتاحة: | https://doi.org/10.4081/aiua.2021.2.143Test http://hdl.handle.net/11615/76668Test |
| رقم الانضمام: | edsbas.4A5FAE9D |
| قاعدة البيانات: | BASE |
| تدمد: | 11243562 |
|---|---|
| DOI: | 10.4081/aiua.2021.2.143 |